^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Diffuse Large B-cell Lymphoma: Suggested Treatment Options...Brentuximab Vedotin for CD30+ disease.
Title:
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Excerpt:
Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.
Source:
Title:
Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker
Excerpt:
...• All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including:o Hodgkin lymphomao T-cell lymphomao Cutaneous T-cell lymphomao DLBCL• Age ≥18• Signed written informed consent form (approved by the Institutional Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures• Measurable disease: on CT scan at least 1 lesion/node with a long axis of > 1.5 cm and at least one positive lesion on 18F-FDG PET scan u2028• WHO performance status 0-2 (see appendix A) u2028• Adequate hepatic function: total bilirubin ≤ 1.5 times ULN (unless due to lymphoma involvement of the liver or a known history of Gilbert's syndrome as defined by > 80% unconjugated bilirubin) and ALAT/ASAT ≤ 3 times ULN (unless due to lymphoma involvement of the liver; in that case ALAT/ASAT may be elevated up to 5 times ULN)• Adequate renal function: GFR > 50 ml/min as estimated by the Cockroft&Gault formula at rehydration: CrCL = (140-age [in years] x weight [kg] (x 0.85 for females) (0.815 x serum creatinine [μmol/L]) u2028• Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelet count ≥100 x 109/L, unless caused by diffuse bone marrow infiltration by lymphoma• Hemoglobin must be ≥ 8 g/dL (5.0 mmol/L), transfusion is allowed u2028• Life expectancy of >3 months with treatment u2028• Negative pregnancy test at study entry, if applicable • Alle patiënten met histologisch bewezen CD30-positieve (d.w.z. ...
Trial ID:
Source:
Title:
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Excerpt:
...PFS per blinded independent central review (BICR) in the intent-to-treat (ITT) population`PFS per BICR in the CD30-positive population...
More C2 evidence
Source:
Title:
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Excerpt:
...- Histologically confirmed CD30-positive, CD20-positive untreated primary mediastinal B-cell lymphoma (any Ann Arbor stage), diffuse large B-cell lymphoma (Ann Arbor stage III or IV), or grey zone lymphoma (any Ann Arbor stage)....
Trial ID:
Source:
Title:
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Excerpt:
...During dose escalation, patients can be either CD30 positive or CD30 negative....
Trial ID:
Source:
Title:
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Excerpt:
...- CD30 positive DLBCL, i.e. more than 1% of DLBCL cells CD30 positive(central pathology review results...
Trial ID:
Source:
Title:
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Excerpt:
...Patients with confirmed CD30-positive DLBCL or grade 3b follicular non-Hodgkin lymphoma (NHL)....
Trial ID:
Source:
Title:
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Excerpt:
...- Patients in Parts 2 and 3 must have histologically confirmed diagnosis of CD30-positive DLBCL...
Trial ID:
Source:
Title:
A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Excerpt:
...Histologically-confirmed CD30-positive disease....
Trial ID:
Less C2 evidence
Source:
Title:
CLINICAL CHARACTERISTICS, PROGNOSTIC FACTORS AND TREATMENT OUTCOMES OF PATIENTS WITH PLASMABLASTIC LYMPHOMA: RETROSPECTIVE ANALYSIS OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGICAL DISEASES
Published date:
06/12/2020
Excerpt:
We reported 17 patients with plasmablastic lymphoma...1 CD30 positive patient received brentuximab vedotin in third line of treatment achieving a short partial response.
